

23 December 2024

**Our Ref:** FOI 352

Dear

**Freedom of Information Act 2000  
Information in relation to Multiple Myeloma**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 11 November 2024. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to each of the questions raised has been provided by the Unscheduled Care, Medicine & Cancer Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital ([informationgovernance@setrust.hscni.net](mailto:informationgovernance@setrust.hscni.net)) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

---

**Rebecca Manning**  
**Information Governance Officer**

**Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.**

**Q2. Of the multiple myeloma patients over the past 6 month, how many were treated with the following:**

- **Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)**
- **Bortezomib, thalidomide and dexamethasone [VTD]**
- **Daratumumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone**
- **Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)**
- **Selinexor, Bortezomib [Velcade] and dexamethasone**
- **Carfilzomib [Kyprolis] and dexamethasone**
- **Bortezomib [Velcade] monotherapy or with dexamethasone**
- **Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)**
- **Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone**
- **Belantamab Mafodotin [Blenrep]**
- **Idecabtagene vicleucef [Abecma]**
- **Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)**
- **Elranatamab**
- **Daratumumab [Darzalex] monotherapy**
- **Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd)**
- **Lenalidomide [Revlimid] and dexamethasone**
- **Lenalidomide [Revlimid] monotherapy**
- **Pomalidomide [Imnovid] and dexamethasone**
- **Selinexor and dexamethasone**
- **Talquetamab**
- **Teclistamab [Tecvayli]**
- **Any other systemic anti-cancer therapy**

A1,2. Due to the new digital system, the information that you have requested is not centrally held in a way which is easily extracted. To obtain this information would require a manual review of records.

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

12.-(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

In accordance with the Freedom of Information Act 2000 this letter acts as a Refusal Notice.